OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Nimer on the Biggest Challenges of MDS

May 1st 2015

Stephen D. Nimer, MD, Director, Professor of Medicine, Sylvester Comprehensive Cancer Center discusses the challenges of treating myelodysplastic syndromes (MDS).

Dr. Hamid on Using Biomarkers for Immunotherapy in Melanoma

May 1st 2015

Omid Hamid, MD, chief, Translational Research and Immunotherapy, director, Melanoma Therapeutics, The Angeles Clinic and Research Institute, discusses the possibility of using biomarkers to select immunotherapy as a treatment option for patients with melanoma.

Dr. Mathew Hall on Risks and Benefits of PSA Screening

April 29th 2015

Mathew Hall, MD, radiation oncologist, City of Hope National Medical Center, discusses prostate cancer screening.

Dr. Kapo on Addressing Palliative Care With Patients

April 29th 2015

Jennifer M. Kapo, MD, chief, palliative medicine, Yale Cancer Center, associate professor of medicine (medical oncology and geriatrics), Yale School of Medicine, discusses how oncologists can address palliative care with their patients.

Dr. Alan Miller on Benefits of Liquid Biopsy

April 29th 2015

Alan M. Miller, MD, PhD, Director of the Baylor Charles A. Sammons Cancer Center and Chief of Oncology for the Baylor Health Care System discusses the benefits of liquid biopsy.

Dr. Steven Coutre on the Eventual Role of Chemotherapy in CLL

April 28th 2015

Steven Coutre, MD, professor of medicine, Stanford University Medical Center, discusses the eventual role chemotherapy will have in the treatment of chronic lymphocytic leukemia.

Dr. Daniel Von Hoff on Combination Treatments for Late Stage Pancreatic Cancer

April 27th 2015

Daniel Von Hoff, MD, the Physician-in-Chief and Director of Translational Research at the Translational Genomics Research Institute (TGen) and a special consult with Baylor University College of Medicine, discuses combination treatments for pancreatic cancer.

Dr. Daniel Brat on Characterizing Diffuse Lower Grade Gliomas

April 27th 2015

Daniel J. Brat, MD, PhD, vice chair, Translational Programs, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, director, Cancer Tissue and Pathology Shared Resource, Winship Cancer Institute, discusses genomic characterization of diffuse lower grade gliomas.

Dr. Thomas Hutson on Drug Sequencing in Renal Cell Carcinoma

April 24th 2015

Thomas E. Hutson, DO, PharmD, medical oncologist, Director of Genito-Urinary at Texas Oncologyâ€“Baylor Charles A. Sammons Cancer Center, discusses drug sequencing for the treatment of renal cell carcinoma.

Dr. Sartor on Sequencing Therapies in Prostate Cancer

April 24th 2015

Oliver Sartor, MD, medical oncologist, Tulane University School of Medicine, discusses sequencing therapies and potential targets in prostate cancer.

Dr. Shaw on Overcoming Resistance in Lung Cancer

April 23rd 2015

Alice Tsang Shaw, MD, PhD, thoracic oncologist, Massachusetts General Hospital Cancer Center, discusses overcoming resistance to targeted therapy in lung cancer.

Dr. Roy Weiner on the Importance of Diversity in Cancer Research

April 17th 2015

Roy Weiner, MD, Associate Dean for Clinical Research and Training Associate Director of Clinical Research for Tulane Cancer Center discusses the importance of racial and ethnic diversity in cancer research.

Dr. Manish Shah on MET Inhibitors Not Improving PFS in MET-Positive GEC

April 17th 2015

Manish A. Shah, MD, director of gastrointestinal oncology, Weill Cornell Medical College/New York Presbyterian Hospital, discusses why MET inhibitors such as onartuzumab do not improve progression-free survival for the treatment of metastatic, HER2-negative gastroesophageal adenocarcinoma.

Dr. Albiges on Implementing mRCC Findings into Practice

April 16th 2015

Laurence Albiges, MD, visiting scientist, Dana-Farber Cancer Institute, discusses how oncologists can treat patients with metastatic renal cell carcinoma (mRCC) based off of findings from a study that looked at the impact of body mass index (BMI) on outcomes of these patients.

Dr. Tracey Evans on Chemotherapy for the Elderly Patient

April 16th 2015

Tracey Evans, MD, Associate Professor of Clinical Medicine University of Pennsylvania Health System, discusses how to determine which patients will benefit from chemotherapy.

Dr. LoRusso on Personalized Medicine for Melanoma

April 15th 2015

Patricia M. LoRusso, DO, Associate Director of Innovative Medicine, Yale Cancer Center, discusses the Dream Team Melanoma trial, which is investigating using personalized medicine to treat non-V600E melanoma subtypes.

Dr. Sznol on Managing Toxicities in Treatment of Melanoma

April 15th 2015

Mario Sznol, MD, professor of medicine (medical oncology), clinical research program leader, Melanoma Program, Yale Cancer Center, discusses how to manage toxicities in treatment of melanoma.

Dr. Komrokji on Optimizing MDS Management

April 14th 2015

Rami S. Komrokji, MD, clinical director, Hematologic Malignancies, Moffitt Cancer Center, discusses optimizing the management of treatment for myelodysplastic syndrome (MDS).

Dr. Michalski on Escalated Dose Radiation Therapy in Prostate Cancer

April 14th 2015

Jeff Michalski, MD, professor, vice chair of Radiation Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses results of a study which compared standard dose radiation therapy to escalated dose for patients with intermediate-risk prostate cancer.

Dr. Markman on the Future of Treatment for Ovarian Cancer

April 13th 2015

Maurie Markman, MD, national director, Cancer Treatment Centers of America, discusses what he sees as future treatment paradigms in ovarian cancer.